Rare Disease ReportGene Therapy for Juvenile Batten Disease Gets Orphan Drug DesignationRare Disease ReportThis is the 4th gene therapy the company has in development that has obtained an Orphan Drug Designation. The other 3 are being developed to trea… Continue reading
Rare Disease ReportGene Therapy for Juvenile Batten Disease Gets Orphan Drug DesignationRare Disease ReportThis is the 4th gene therapy the company has in development that has obtained an Orphan Drug Designation. The other 3 are being developed to trea… Continue reading
|
€40M in Series C for a British Biotech Treating Blindness with Gene Therapy
Labiotech.eu (blog) NightstaRx has raised €39.5M that will go towards three clinical programs testing gene therapies for rare diseases that cause blindness. NightstaRx is developing gene therapies for genetic retinal diseases that cause blindness, with technology from the … |
|
€40M in Series C for a British Biotech Treating Blindness with Gene Therapy
Labiotech.eu (blog) NightstaRx is developing gene therapies for genetic retinal diseases that cause blindness, with technology from the University of Oxford. Now getting closer to the clinic, the company has closed a Series C round with $45M (€39.5M) that will go towards … |
|
NightstaRx Raises $45M to Fund Phase III Study with Retinal Disease Gene Therapy
Genetic Engineering & Biotechnology News (blog) U.K. firm NightstaRx raised $45 million in a Series C financing round to support continued clinical development of its pipeline of retinal gene therapies, including a pending Phase III study with lead candidate NSR-REP1 for treating choroideremia. The … |
|
Mosquito suppression on ‘continental scale’ could be possible with CRISPR
Genetic Literacy Project Scientists at UC Berkeley and UC Riverside have demonstrated a way to edit the genome of disease-carrying mosquitoes that brings us closer to suppressing them on a continental scale. The study used CRISPR/Cas9 gene-editing technology to insert and … |